Zobrazeno 1 - 6
of 6
pro vyhledávání: '"James E. Morgado"'
Autor:
Arani Chanda, Shailendra Bordawekar, Samrat Mukherjee, John P. Higgins, Howard W. Ward, Mark A. LaPack, Adrian M. Daly, Bing-Shiou Yang, John D. Orr, James E. Morgado, Todd D. Maloney, George L. Reid, Aaron W. Garrett
Publikováno v:
Organic Process Research & Development. 19:1174-1185
The IQ Consortium reports on the current state of process analytical technology (PAT) for active pharmaceutical ingredient (API) manufacturing in branded pharmaceutical companies. The article describes the application of PAT in manufacturing and prov
Autor:
David Fortin, Guilong Cheng, Gang Xue, George L. Reid, James E. Morgado, Jian Wang, Jeffrey W. Harwood
Publikováno v:
Journal of Liquid Chromatography & Related Technologies. 36:2612-2638
The Analytical Quality by Design (AQbD) concept is demonstrated in the development of a stability-indicating HPLC method for an immediate release dosage form. The AQbD workflow is discussed and demonstrated with a systematic three stage liquid chroma
Autor:
Gang Xue, David Fortin, George L. Reid, Koji Muteki, Jeffrey W. Harwood, James E. Morgado, Ian J. Miller, Frank Riley, Jian Wang
Publikováno v:
Industrial & Engineering Chemistry Research. 52:12269-12284
Quantitative structure retention relationships (QSRRs) can play an important role in enhancing the speed and quality of chromatographic method development. This paper presents a novel (compound-classification-based) QSRR modeling strategy that simult
Autor:
Elizabeth A. MacLean, Lillian Shahied Arruda, James E. Morgado, Diane Lorraine Borst, Yazdi K. Pithavala
Publikováno v:
American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists. 71(13)
Purpose An overview of the responses to some of the most frequently asked questions regarding axitinib administration and dosage modifications used in clinical practice are presented. Summary Axitinib was approved for second-line treatment of advance
Autor:
Elizabeth A. MacLean, Nikhil Sharma, Diane Lorraine Borst, Lillian Shahied Arruda, James E. Morgado, Yazdi K. Pithavala
Publikováno v:
Journal of Clinical Oncology. 32:538-538
538 Background: Axitinib is a next generation VEGFR inhibitor approved in the US in Jan 2012 for advanced RCC after failure of one prior systemic therapy. Post approval questions may arise in the medical community regarding clinical scenarios which m
Autor:
Borst DL; Diane L. Borst, Pharm.D., is Director, Regional Medical Research Specialists, U.S. Medical Affairs, Pfizer, New York, NY. Lillian S. Arruda, Ph.D., is Associate Director, Oncology Medical Information, Pfizer, Collegeville, PA. Elizabeth MacLean, Pharm.D., is Director, U.S. Health Economics and Outcomes Research-Oncology, Pfizer, New York, NY. Yazdi K. Pithavala, Ph.D., is Senior Director, Clinical Pharmacology, Pfizer, San Diego, CA. James E. Morgado, B.Sc., is Principal Scientist, Chemistry-Analytics, Pfizer, Groton, CT. diane.l.borst@pfizer.com., Arruda LS; Diane L. Borst, Pharm.D., is Director, Regional Medical Research Specialists, U.S. Medical Affairs, Pfizer, New York, NY. Lillian S. Arruda, Ph.D., is Associate Director, Oncology Medical Information, Pfizer, Collegeville, PA. Elizabeth MacLean, Pharm.D., is Director, U.S. Health Economics and Outcomes Research-Oncology, Pfizer, New York, NY. Yazdi K. Pithavala, Ph.D., is Senior Director, Clinical Pharmacology, Pfizer, San Diego, CA. James E. Morgado, B.Sc., is Principal Scientist, Chemistry-Analytics, Pfizer, Groton, CT., MacLean E; Diane L. Borst, Pharm.D., is Director, Regional Medical Research Specialists, U.S. Medical Affairs, Pfizer, New York, NY. Lillian S. Arruda, Ph.D., is Associate Director, Oncology Medical Information, Pfizer, Collegeville, PA. Elizabeth MacLean, Pharm.D., is Director, U.S. Health Economics and Outcomes Research-Oncology, Pfizer, New York, NY. Yazdi K. Pithavala, Ph.D., is Senior Director, Clinical Pharmacology, Pfizer, San Diego, CA. James E. Morgado, B.Sc., is Principal Scientist, Chemistry-Analytics, Pfizer, Groton, CT., Pithavala YK; Diane L. Borst, Pharm.D., is Director, Regional Medical Research Specialists, U.S. Medical Affairs, Pfizer, New York, NY. Lillian S. Arruda, Ph.D., is Associate Director, Oncology Medical Information, Pfizer, Collegeville, PA. Elizabeth MacLean, Pharm.D., is Director, U.S. Health Economics and Outcomes Research-Oncology, Pfizer, New York, NY. Yazdi K. Pithavala, Ph.D., is Senior Director, Clinical Pharmacology, Pfizer, San Diego, CA. James E. Morgado, B.Sc., is Principal Scientist, Chemistry-Analytics, Pfizer, Groton, CT., Morgado JE; Diane L. Borst, Pharm.D., is Director, Regional Medical Research Specialists, U.S. Medical Affairs, Pfizer, New York, NY. Lillian S. Arruda, Ph.D., is Associate Director, Oncology Medical Information, Pfizer, Collegeville, PA. Elizabeth MacLean, Pharm.D., is Director, U.S. Health Economics and Outcomes Research-Oncology, Pfizer, New York, NY. Yazdi K. Pithavala, Ph.D., is Senior Director, Clinical Pharmacology, Pfizer, San Diego, CA. James E. Morgado, B.Sc., is Principal Scientist, Chemistry-Analytics, Pfizer, Groton, CT.
Publikováno v:
American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists [Am J Health Syst Pharm] 2014 Jul 01; Vol. 71 (13), pp. 1092-6.